Enhancement of cisplatin sensitivity in lewis lung carcinoma by liposome-mediated delivery of a survivin mutant

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Yu, Dan Dan ^a,b   Wang, Chun Ting ^a   Shi, Hua Shan ^a   Li, Zhi Yong ^a   Pan, Li ^a   Yuan, Qing Zhong ^a   Leng, Fei ^a   Wen, Yuan ^a   Chen, Xiang ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b Henan People's Armed Police Corps Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CISPLATIN; LIPOSOME; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; C57BL MOUSE; DRUG POTENTIATION; GENE THERAPY; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MUTATION; NEOVASCULARIZATION (PATHOLOGY);

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FEMALE; GENE THERAPY; LIPOSOMES; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77952004339     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-46     Document Type: Article

References (30)

1. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
2. Altieri DC: Xa receptor EPR-1. FASEB J 1995, 9:860-865.
3. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002, 86:886-892.
4. Sanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001, 93:1541-1552.
5. Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N: Ribozymemediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002, 109: 285-286.
6. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, Zaffaroni N: Silencing of survivin gene by small interfering RNAs produces supraadditive growth suppression in combination with 17-allylamino-17- demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006, 5: 179-186.
7. Jiang G, Li J, Zeng Z, Xian L: Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 2006, 5:435-440.
8. Pisarev V, Yu B, Salup R, Sherman S, Gabrilovich DI: Full-length dominantnegative survivin for cancer immunotherapy. Clin Cancer Res 2003, 9:6523-6533.
9. Grossman D, Kim PJ, Schechner JS, Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001, 98:635-640.
10. Daniel S, O'Connor, Grossman Douglas: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of surviving. Proc Natl Acad Sci USA 2000, 97:13103-13107.
11. McKay TR, Bell S, Tenev T, Stoll V, Lopes R, Lemoine NR, McNeish IA: Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A, a combination gene therapy strategy. Oncogene 2003, 22:3539-3547.
12. Peng XC, Yang L, Wei YQ, et al.: Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34TAla mutant. J Exp Clin Cancer Res 2008, 27:46.
13. Zaffaroni N, Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resistance Updates 2002, 5:65-72.
14. Loehrer PJ, Einhorn LH: Drugs five years later. Cisplatin. Ann Intern Med 1984, 100:704-713.
15. Evans DL, Tilby M, Dive C: Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res 1994, 54:1596-1603.
16. Morazzoni F, Canevali C, Zucchetti M, Caroli S, Alimonti A, Petrucci F, Giudice G, Masoni E, Bedini AV: cis-Diamminedichloroplatinum(II) given in continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: A pharmacokinetic approach. Cancer Res Clin Oncol 1998, 24: 137-43.
17. Kurihara N, Kubota T, Hoshiya Y, et al.: Antitumor activity of cisdiamminedichloroplatinum (II) depends on its time × concentration product against human gastric cancer cell lines in vitro. J Surg Oncol 1995, 60:238-241.
18. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
19. Li F, Ambrosini G, Chu EY, et al.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396: 580-583.
20. Tamm I, Wang Y, Sausville E, et al.: IAP-family protein survivin inhibits caspase activity and apoptosis induced bf Fas(CD96), Bax, caspase, and anticancer drugs. Cancer Res 1998, 58:5315-5320.
21. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC: Developmentally regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998, 152:43-49.
22. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 1999, 248:30-47.
23. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998, 58:5071-5074.
24. LaCasse EC, Baird S, Korneluk RG, Mackenzie AE: The inhibitors of apoptosis IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259.
25. Grossman D, McNiff JM, Li F, Altieri DC: Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999, 79:1121-1126.
26. Yamamoto T, Manome Y, Nakamura M, Tanigawa N: Down regulation of survivin expression by induction of the effector cell protease receptor- 1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002, 38:2316-2324.
27. Olie RA, Simones-Wust AP, Baumann B, et al.: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000, 60: 2805-2809.
28. Li F, Ackermann EJ, Bennett CF, et al.: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999, 1:461-466.
29. Hiromi K, Minoru I, et al.: Enhancement of Cisplatin Sensitivity in Squamous Cell Carcinoma of the Head and Neck Transfected With a Survivin Antisense Gene. Archoto head neck surg 2006, 132:682-685.
30. Kuwahara D: Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Letters 2000, 148:65-71.